Expertise in
13
conditions

Dr. Mohan K. Tummala

Hematology
Office
2055 S Fremont Ave Ste 1000, 
Springfield, MO 
Accepting New Patients
Expertise in
13
conditions
Office
2055 S Fremont Ave Ste 1000, 
Springfield, MO 

Overview

Mohan Tummala is a Hematologist practicing medicine in Springfield, Missouri.

Dr. Tummala is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Large-Cell Immunoblastic Lymphoma, ALK-Positive Non-Small Cell Lung Cancer, Multiple Myeloma, Castleman Disease, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 5 peer reviewed articles and participating in 6 clinical trials. Dr. Tummala is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in MO

Hospital Affiliations

Mercy Hospital Aurora
Mercy Hospital Springfield
Mercy St Francis Hospital
Mercy Hospital Lebanon

Languages Spoken

English
Telugu

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Office
2055 S Fremont Ave Ste 1000, Springfield, MO 65804

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Phase 3, Open-Label, 4-Cohort Study of Nogapendekin Alfa Inbakicept in Combination With Current Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 3, Open-Label, 4-Cohort Study of Nogapendekin Alfa Inbakicept in Combination With Current Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: May 26, 2026
Intervention Type: Drug
Study Drugs: N-803+Pembrolizumab, N-803+Carboplatin+Nab-paclitaxel+Pembrolizumab, N-803+Cisplatin or Carboplatin+Pembrolizumab+Pemetrexed, Pembrolizumab, Carboplatin+Nab-paclitaxel or Paclitaxel+Pembrolizumab, Cisplatin or Carboplatin+Pembrolizumab+Pemetrexed
Study Phase: Phase 3
QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2026
Intervention Type: Drug
Study Drugs: N-803, Pembrolizumab, Nivolumab, Atezolizumab, Avelumab, Durvalumab, PD-L1 t-haNK
Study Phase: Phase 2
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drug: Canakinumab
Study Phase: Phase 3
The Circulating Cell-free Genome Atlas Study
The Circulating Cell-free Genome Atlas Study
Enrollment Status: Unknown
Publish Date: September 13, 2023
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Enrollment Status: Completed
Publish Date: September 01, 2022
Intervention Type: Other
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Hematologic Malignancies
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Hematologic Malignancies
Enrollment Status: Terminated
Publish Date: February 03, 2021
Intervention Type: Other
View 5 Less Clinical Trials

5 Total Publications

Multi-cancer early detection test sensitivity for cancers with and without current population-level screening options.
Multi-cancer early detection test sensitivity for cancers with and without current population-level screening options.
Journal: Tumori
Published: November 01, 2022
Similar Doctors
Expertise in
28
conditions
Expertise in
28
conditions
Referral may be required

Mercy Children's Hospital Springfield

1235 E Cherokee St, 
Springfield, MO 
 (2.4 miles away)
417-820-2000
Languages Spoken:
English, Hindi, Telugu
See accepted insurances
Accepting New Patients

Lavanya Tiriveedhi is a Hematologist practicing medicine in Springfield, Missouri. Dr. Tiriveedhi is highly rated in 28 conditions, according to our data. Her clinical expertise encompasses Philadelphia-Negative Chronic Myeloid Leukemia, Chronic Myelogenous Leukemia (CML), Richter Syndrome, and Chronic Lymphocytic Leukemia (CLL). Dr. Tiriveedhi is currently accepting new patients.

Expertise in
22
conditions
Expertise in
22
conditions
Referral may be required

Mercy Therapy Services-Branson Highway 248

448 State Highway 248, 
Branson, MO 
 (33.2 miles away)
417-334-7647
Languages Spoken:
English, German, Malay, Malayalam, Malayan
See accepted insurances
Accepting New Patients
Offers Telehealth

Rajesh Nair is a Hematologist practicing medicine in Branson, Missouri. Dr. Nair is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Chronic Myelogenous Leukemia (CML), Philadelphia-Negative Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia (CLL), and Richter Syndrome. Dr. Nair is currently accepting new patients.

Expertise in
27
conditions
Expertise in
27
conditions
Referral may be required

Central Care PA

1501 N Oakland Ave, 
Bolivar, MO 
 (34.2 miles away)
417-326-7200
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Penelope Harris is a Hematologist practicing medicine in Bolivar, Missouri. Dr. Harris is highly rated in 27 conditions, according to our data. Her clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, Essential Thrombocythemia, and Thrombocytopenia. Dr. Harris is currently accepting new patients.

Frequently Asked Questions about Dr. Mohan K. Tummala

How do I make an appointment with Dr. Mohan K. Tummala?

You can book an appointment with Dr. Mohan K. Tummala by calling their office at 417-820-8099. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mohan K. Tummala a top-rated expert for Large-Cell Immunoblastic Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mohan K. Tummala is classified as an Advanced expert for Large-Cell Immunoblastic Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mohan K. Tummala specialize in?

While Dr. Mohan K. Tummala is a Hematology, they have specific expertise in Large-Cell Immunoblastic Lymphoma, ALK-Positive Non-Small Cell Lung Cancer, and Multiple Myeloma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Mohan K. Tummala participate in research or clinical trials?

Yes. Dr. Mohan K. Tummala has published 5 articles and abstracts on conditions like Large-Cell Immunoblastic Lymphoma. You can view a list of Dr. Mohan K. Tummala's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mohan K. Tummala accept my insurance?

Dr. Mohan K. Tummala accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 417-820-8099 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tummala's expertise for a condition
ConditionClose
      View All 13 Advanced Conditions
      View All 50 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile